The invention relates to phosphohistidine analogs. The invention also relates to antibodies that specifically bind to the analogs and methods of generating said antibodies. In one embodiment of the invention there is provided a phosphohistidine analog of Formula V: (V) wherein W is selected from H, CO.sub.2H or CONH.sub.2; and X is selected from CH or N. ##STR00001##

The invention relates to phosphohistidine analogs. The invention also relates to antibodies that specifically bind to the analogs and methods of generating said antibodies. In one embodiment of the invention there is provided a phosphohistidine analog of Formula V: (V) wherein W is selected from H, CO.sub.2H or CONH.sub.2; and X is selected from CH or N. ##STR00001##

The present disclosure provides phosphonate-containing heterocycle compounds with TYK2 kinase inhibitory activity, pharmaceutical compositions comprising the same, and applications thereof. The present disclosure provides compounds of Formula (I), as inhibitors of TYK2 kinase. These compounds can be used for preventing and/or treating TYK2 kinase-related diseases and/or conditions.

##STR00001##

This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. ##STR00001##

The present invention relates to novel compounds and probes which have a common chemical structure necessary to obtain potent inhibitory activity against KLK4 and/or may be used for the detection of KLK4 peptides and their activity. It further relates to the use of these compounds and methods for inhibiting and/or detecting KLK4 activity in vitro and in vivo by making use of said probes or inhibitors. The compounds of the invention differ from prior art compounds at least in the presence of phenyl guanidine (instead of e.g. benzyl guanidine) and/or the presence of a heteroatom in the tail group, their combined presence unexpectedly leading to potent and selective KLK4 inhibitory activity.

A heteroleptic binuclear copper(I) complex of the Cu.sub.2X.sub.2(E?N*)L.sub.2 form, having a structure of formula A: ##STR00001##
The copper(I) complex may be used in optoelectronic components, particularly for use in organic light emitting diodes (OLEDs).

A heteroleptic binuclear copper(I) complex of the Cu.sub.2X.sub.2(E?N*)L.sub.2 form, having a structure of formula A: ##STR00001##
The copper(I) complex may be used in optoelectronic components, particularly for use in organic light emitting diodes (OLEDs).

Novel inhibitors of DXP synthase and methods of use thereof are disclosed.

Novel inhibitors of DXP synthase and methods of use thereof are disclosed.

It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.